Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean‐Charles Soria(Inserm), Tony Mok(Chinese University of Hong Kong), Jianying Zhou(First Affiliated Hospital Zhejiang University), Kiyotaka Yoh(National Cancer Center Hospital East), James Chih‐Hsin Yang(National Taiwan University Hospital), Haiyi Jiang(AstraZeneca (Japan)), Shinji Atagi(National Institute of Technology, Nara College), Xiaojin Shi, Alan Webster(AstraZeneca (United Kingdom)), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), You Lü(Sichuan University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Yunpeng Liu(Shenyang Institute of Automation), Jin-Ji Yang(Guangdong General Hospital), Sang-We Kim(Asan Medical Center), Ki Hyeong Lee(Chungbuk National University Hospital), Santiago Ponce(Spanish National Cancer Research Centre), Myung‐Ju Ahn(Sungkyunkwan University)
Cited by 412
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k